Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature.

Tytuł:: Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature.
Autorzy:: Aickara DJ; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Leonard M. Miller School of Medicine, University of Miami, Coral Gables, Florida.
McBride J; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Leonard M. Miller School of Medicine, University of Miami, Coral Gables, Florida.
Morrison B; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Leonard M. Miller School of Medicine, University of Miami, Coral Gables, Florida.
Romanelli P; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Leonard M. Miller School of Medicine, University of Miami, Coral Gables, Florida.
Źródło:: Journal of cutaneous pathology [J Cutan Pathol] 2020 Apr; Vol. 47 (4), pp. 398-401. Date of Electronic Publication: 2019 Nov 25.
Typ publikacji:: Case Reports
Język:: English
Imprint Name(s):: Publication: Malden, MA : Wiley
Original Publication: Copenhagen, Blackwell Munksgaard.
MeSH Terms:: Drug Resistance, Neoplasm*
Gastrointestinal Neoplasms*/drug therapy
Gastrointestinal Neoplasms*/genetics
Gastrointestinal Neoplasms*/metabolism
Gastrointestinal Neoplasms*/pathology
Gastrointestinal Stromal Tumors*/drug therapy
Gastrointestinal Stromal Tumors*/genetics
Gastrointestinal Stromal Tumors*/metabolism
Gastrointestinal Stromal Tumors*/pathology
Proto-Oncogene Proteins c-kit*/genetics
Proto-Oncogene Proteins c-kit*/metabolism
Skin Neoplasms*/genetics
Skin Neoplasms*/metabolism
Skin Neoplasms*/pathology
Skin Neoplasms*/secondary
Imatinib Mesylate/*administration & dosage
Protein Kinase Inhibitors/*administration & dosage
Sunitinib/*administration & dosage
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Neoplasm Metastasis
References:: Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22(18):3813-3825.
Jumniensuk C, Charoenpitakchai M. Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis. World J Surg Oncol. 2018;16(1):231.
Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-1134.
Kim YJ, Lee WJ, Won CH, Choi JH, Lee MW. Metastatic cutaneous duodenal gastrointestinal stromal tumor: a possible clue to multiple metastases. Ann Dermatol. 2018;30(3):345-347.
Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007;13(16):4874-4881.
Shabahang M, Livingstone AS. Cutaneous metastases from a gastrointestinal stromal tumor of the stomach: review of literature. Dig Surg. 2002;19(1):64-65.
Hughes B, Yip D, Goldstein D, Waring P, Beshay V, Chong G. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer. 2004;4:74.
Kroep JR, Bovee JV, van der Molen AJ, Hogendoorn PC, Gelderblom H. Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. J Cutan Pathol. 2009;36(5):565-569.
Wang WL, Hornick JL, Mallipeddi R, et al. Cutaneous and subcutaneous metastases of gastrointestinal stromal tumors: a series of 5 cases with molecular analysis. Am J Dermatopathol. 2009;31(3):297-300.
Na YS, Ryu MH, Yoo C, et al. Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors. Oncotarget. 2017;8(44):76712-76721.
Contributed Indexing:: Keywords: cutaneous; cutaneous metastasis; gastric cancer; gastrointestinal stromal tumors; neoplasm metastasis; skin
Substance Nomenclature:: 0 (Protein Kinase Inhibitors)
8A1O1M485B (Imatinib Mesylate)
EC 2.7.10.1 (KIT protein, human)
EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
V99T50803M (Sunitinib)
Entry Date(s):: Date Created: 20191109 Date Completed: 20201204 Latest Revision: 20201214
Update Code:: 20240105
DOI:: 10.1111/cup.13611
PMID:: 31702819
: Raport

Pełny tekst

Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms which account for less than 1% of all gastrointestinal malignancies. Of all the extra-abdominal metastases of GIST, superficial soft tissue metastases are the rarest. Previous reports have found success with sunitinib in imatinib-resistant GIST, but we report a certain wild-type KIT mutation GIST with cutaneous and subcutaneous metastasis that was unresponsive to multiple tyrosine kinase inhibitor (TKI) treatments. This case illustrates that knowing the specific type of KIT mutations may uncover resistance of certain GIST's to TKIs, necessitating more targeted and alternative therapy.
(© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja